Abstract: The present disclosure relates to a method of hydrolysis of at least one proteinaceous substrate using at least one organic acid, resulting in a hydrolysate that has Angiotensin Converting Enzyme activity inhibitory potential.
CLIAMS:1. A process for hydrolysis of at least one proteinaceous substrate to obtain a hydrolysate, said process comprising the steps of:
(a) obtaining at least one proteinaceous substrate;
(b) contacting said proteinaceous substrate with at least one organic compound to obtain a mixture and incubating said mixture at a temperature in the range of 22-30°C, at a pH in the range of 0.9-4, for a time period ranging from 0-0.5 hours to obtain a substrate;
(c) contacting said substrate from step (b) with at least one protease and incubating at a temperature in the range of 45-55°C, at a pH in the range of 5.5-7.5, for a time period in the range of 1-5 hours; and
(d) inactivating said protease from step (c) to obtain a hydrolysate,
wherein said hydrolysate inhibits angiotensin converting enzyme activity.
2. The process as claimed in claim 1, wherein said process optionally further comprises the step of centrifuging said hydrolysate obtained from step (d) at 10000-13000 rpm for 15-30 minutes to obtain a supernatant fraction.
3. The process as claimed in any of the claims 1-2, wherein said at least one proteinaceous substrate is selected from the group consisting of WPC-70, WPC-80, milk protein concentrate, milk protein isolate, and combinations thereof.
4. The process as claimed in any of the claims 1-2, wherein said at least one organic compound is selected from the group consisting of acetic acid, citric acid, and combinations thereof.
5. The process as claimed in any of the claims 1-2, wherein said at least one protease is selected from the group consisting of trypsin, pepsin, thermolysin, chymotrypsin, proteinase K, aminopeptidase, papain, actinase, renin, acid proteases, and combinations thereof.
6. Use of a process as claimed in any of the claims 1-5 to obtain a hydrolysate with angiotensin converting enzyme inhibitory activity.
,TagSPECI:As Attached
| # | Name | Date |
|---|---|---|
| 1 | PD016442IN-SC SPEC FOR FILING.pdf | 2015-07-08 |
| 2 | PD016442IN-SC FORM 5.pdf | 2015-07-08 |
| 3 | PD016442IN-SC FORM 3.pdf | 2015-07-08 |
| 4 | PD016442IN-SC FIGURES FOR FILING.pdf | 2015-07-08 |
| 5 | 3482-CHE-2015 POWER OF ATTORNEYT10-08-2015.pdf | 2015-08-10 |
| 6 | 3482-CHE-2015 FORM-1 10-08-2015.pdf | 2015-08-10 |
| 7 | 3482-CHE-2015 CORRESPONDENCE OTHERS 10-08-2015.pdf | 2015-08-10 |
| 8 | 3482-CHE-2015-FORM 18 [12-06-2019(online)].pdf | 2019-06-12 |
| 9 | 3482-CHE-2015-FER.pdf | 2021-10-17 |
| 1 | patseersearchE_29-07-2021.pdf |